A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

July 3, 2026

Study Completion Date

December 31, 2027

Conditions
Chronic Graft-versus-host-disease
Interventions
DRUG

INCA034176

IV infusion

Trial Locations (9)

101149

RECRUITING

Peking University People'S Hospital, Beijing

200127

RECRUITING

Shanghai Children'S Medical Center, Shanghai

301617

RECRUITING

Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin

310006

NOT_YET_RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine (Fahzu), Hangzhou

400037

RECRUITING

The Second Affiliated Hospital, Army Medical University (Xinqiao Hospital), Chongqing

430022

RECRUITING

Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

510280

RECRUITING

Zhujiang Hospital of Southern Medical University, Guangzhou

510515

RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT06843408 - A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | Biotech Hunter | Biotech Hunter